03:23:11 Europe / Stockholm
Svenska | English

Bio-Works Technologies

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-21 Bokslutskommuniké 2024
2024-08-23 Kvartalsrapport 2024-Q2
2024-05-27 Ordinarie utdelning BIOWKS 0.00 SEK
2024-05-24 Årsstämma 2024
2024-02-19 Bokslutskommuniké 2023
2023-08-18 Kvartalsrapport 2023-Q2
2023-05-29 Ordinarie utdelning BIOWKS 0.00 SEK
2023-05-26 Årsstämma 2023
2023-02-17 Bokslutskommuniké 2022
2022-08-19 Kvartalsrapport 2022-Q2
2022-05-23 Ordinarie utdelning BIOWKS 0.00 SEK
2022-05-20 Årsstämma 2022
2022-05-06 Ordinarie utdelning BIOWKS 0.00 SEK
2022-02-18 Bokslutskommuniké 2021
2021-11-25 Extra Bolagsstämma 2021
2021-08-20 Kvartalsrapport 2021-Q2
2021-05-24 Ordinarie utdelning BIOWKS 0.00 SEK
2021-05-21 Årsstämma 2021
2021-02-19 Bokslutskommuniké 2020
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-18 Ordinarie utdelning BIOWKS 0.00 SEK
2020-05-15 Årsstämma 2020
2020-02-14 Bokslutskommuniké 2019
2019-10-18 Kvartalsrapport 2019-Q3
2019-08-23 Kvartalsrapport 2019-Q2
2019-05-27 Ordinarie utdelning BIOWKS 0.00 SEK
2019-05-17 Årsstämma 2019
2019-04-29 Kvartalsrapport 2019-Q1
2019-02-22 Bokslutskommuniké 2018
2018-08-19 Kvartalsrapport 2018-Q2
2018-05-21 Ordinarie utdelning BIOWKS 0.00 SEK
2018-05-18 Årsstämma 2018
2018-02-19 Bokslutskommuniké 2017

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Bio-Works Technologies är verksamt inom bioteknik. Bolaget utvecklar produkter som separerar och renar molekyler vid framställning av läkemedel. Teknologin baseras på kromatografi som har som avsikt att hantera läkemedelssubstansen. Kunderna återfinns inom den europeiska marknaden där produkterna säljs via distributionspartners och till bolag inom läkemedelsindustrin, samt forskningsinstitut och universitet. Bolaget bildades 2006 och har sitt huvudkontor i Uppsala.
Bio-Works secures 0.8 MSEK order for gene therapy manufacturing
2023-10-25 08:20:00

Bio-Works has confirmed a new order for a customized, prepacked solution worth 0.8 MSEK to be used in a viral vector manufacturing process. The initial order is for process validation runs, and the potential annual revenue from the project is estimated to be between 3-12 MSEK.

The customer is an American contract manufacturer of gene therapy products.

“I am happy to see that our focus on customized solutions is paying off,” said Jonathan Royce, CEO at Bio-Works. “Bio-Works is providing solutions to biotech companies that other suppliers cannot offer, and we are making good progress to securing our position as the tailor of biomolecule purification.”

The order is confirmed for delivery in Q1 2024.

Contacts
For more information, please visit the Bio-Works homepage at, www.bio-works.com or contact: Jonathan Royce, CEO, e-mail: jonathan.royce@bio-works.com, phone: +46 70 1434143.

About Bio-Works
Bio-Works enables scientists to achieve their purification goals, from laboratory research to large scale bioprocess production. Our vision is a biotech industry that embraces, develops and builds on new methods and novel ideas. WorkBeads™, Bio-Works’ next-generation, agarose-based products, are used to purify proteins, peptides and other biomolecules, resulting in purer therapies and safer diagnostics. Through collaboration with customers and partners, we develop purification solutions that make important medicines available and accessible to everyone.

Bio-Works’ headquarters, with R&D and manufacturing, is located in Uppsala Business Park in Uppsala, Sweden. We supply products globally, through a combination of direct sales and via distributors in Europe, North America and Asia. The company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Nasdaq First North (“BIOWKS”), and FNCA Sweden AB, +46 (0) 8-528 00 399, info@fnca.se, is appointed Certified Adviser. For more information, www.bio-works.com.

This information is information that Bio-Works Technologies is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-10-25 08:20 CEST.

Attachments
Bio-Works secures 0.8 MSEK order for gene therapy manufacturing

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden